Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 201–300 of 1,000
The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Zhang, S., Chen, W., Zhou, J., Liang, Q., Zhang, Y., Su, M., Zhang, Z., & Qu, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s499403 · Cited by 128
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 126
“The proportion of patients who experienced a durable response was higher in patients treated with anti–PD-1/PD-L1 agents than in those treated with anti–CTLA-4 agents, which is in line with long-term survival data that have been reported for these drugs(15,16) and with the fact that anti–PD-1 agents were demonstrated…”
ResultBar, J., Markel, G., Gottfried, T., Percik, R., Leibowitz‐Amit, R., Berger, R., Golan, T., Daher, S., Taliansky, A., Dudnik, E., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.021 · Cited by 113
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
“The CHECKMATE-238 trial compared adjuvant therapy with nivolumab versus ipilimumab in those with resected stage III or IV melanoma and confirmed the superiority of nivolumab: the 12-month rate of recurrence-free survival was 71% in the nivolumab group and 61% in the ipilimumab group [58].”
MethodSelf-citationNew insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 113
“mAbs targeting PD-1 (nivolumab, pembrolizumab, cemiplimab) (17-20) and PD-L1 (atezolizumab, durvalumab, avelumab) (21-29) have also shown clinical response in multiple solid and hematologic tumors.”
BackgroundCutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 124
“Nivolumab improved RFS compared to ipilimumab with lower toxicities (34).”
Immunotherapy for Non-melanoma Skin Cancer
Shalhout, S. Z., Emerick, K. S., Kaufman, H. L., & Miller, D. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01120-z · Cited by 108
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 115
Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., Meric‐Bernstam, F., Wang, Y., Levy, J., Grindheim, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0450 · Cited by 112
“The protocol was approved by the institutional review board/ethics committee at each trial center All”
Kang, Y., Terashima, M., Kim, Y., Boku, N., Chung, H. C., Chen, J., Ji, J., Yeh, T., Chen, L., Ryu, M., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00156-0 · Cited by 115
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., Brochez, L., del Mármol, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115153 · Cited by 136
Self-citationChen, D., Menon, H., Verma, V., Guo, C., Ramapriyan, R., Barsoumian, H. B., Younes, A. I. A., Hu, Y. Y., Wasley, M. D., Cortez, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000492 · Cited by 108
Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses
Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 115
“36,37 It is also possible that a decrease in tumor bulk or epitope spreading 38 that results from a response to ICIs might contribute to the emergence of late irAEs.”
BackgroundImmunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 109
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 110
“There were 35 studies with ICI alone arms totaling 13,956 patients (Supplemental Table 3).(36-71) Disease sites include cancers of head and neck, 42 stomach, 68 melanoma, 47, 50, 51, 56, 58, 59, 61, 62, 67, 70, 71 lung, 43-45, 55, 57, 60, 63, 64, 69 kidney, 53, 54, 65 prostate,(36) and urothelial origin.”
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 106
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Morello, S., Capone, M., Sorrentino, C., Giannarelli, D., Madonna, G., Mallardo, D., Grimaldi, A. M., Pinto, A., & Ascierto, P. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1348-8 · Cited by 108
“5% of patients experience any grade treatment-related effects [21].”
BackgroundSelf-citationNeoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Long, G. V., Menzies, A. M., & Scolyer, R. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02575 · Cited by 109
Self-citationEggermont, A. M. M., Kiciński, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114327 · Cited by 120
Self-citationRecent advances in targeted nanomedicine as promising antitumor therapeutics
Hejmady, S., Pradhan, R., Alexander, A., Agrawal, M., Singhvi, G., Gorain, B., Tiwari, S., Kesharwani, P., & Dubey, S. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.031 · Cited by 99
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
Fletcher, K. A., & Johnson, D. B. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008591 · Cited by 115
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 110
Gastman, B., Gerami, P., Kurley, S. J., Cook, R. W., Leachman, S. A., & Vetto, J. T. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.028 · Cited by 98
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Rozeman, E. A., Dekker, T. J. A., Haanen, J. B. A. G., & Blank, C. U. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0325-6 · Cited by 109
“It was recently shown that adjuvant nivolumab resulted in significantly longer RFS and a lower grade 3/4 toxicity rate compared with adjuvant ipilimumab [136].”
BackgroundRoutman, D. M., Garant, A., Lester, S. C., Day, C. N., Harmsen, W. S., Sanheuza, C. T., Yoon, H. H., Neben-Wittich, M. A., Martenson, J. A., Haddock, M. G., et al. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.09.004 · Cited by 96
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020
Gupta, S., Cortazar, F. B., Riella, L. V., & Leaf, D. E. (2020) · Kidney360 · doi:10.34067/kid.0000852019 · Cited by 102
“ICPIs have been demonstrated to prolong overalland progression-free survival in patients with melanoma (3,4), nonsmall-cell lung cancer (5,6), urothelial cancer (7,8), renal cell cancer (9,10), and many other malignancies (11,12), becoming first-line therapies for many types of cancer.”
BackgroundEngineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Immune checkpoint inhibitors to treat cutaneous malignancies
M.S, D. M. B., Do, M. H., Phillips, G. S., Postow, M. A., Akaike, T., Nghiem, P., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.131 · Cited by 104
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck-Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J.-E. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 96
Schoenfeld, J. D., Nishino, M., Severgnini, M., Manos, M. P., Mak, R. H., & Hodi, F. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0583-3 · Cited by 98
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Asher, N., Ben‐Betzalel, G., Ari, S. L., Shapira‐Frommer, R., Steinberg‐Silman, Y., Gochman, N., Schachter, J., Meirson, T., & Markel, G. (2020) · Cancers · doi:10.3390/cancers12082329 · Cited by 95
“In addition, PD-1 inhibitors were recently approved as an adjuvant treatment for the American Joint Committee on Cancer (AJCC) stage III melanoma, reducing the hazard ratios for disease recurrence compared to placebo [12] and to ipilimumab by half [13].”
BackgroundThe Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)
Bello, D. M., & Faries, M. B. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07830-w · Cited by 92
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
“Recent comparison of nivolumab and ipilimumab as adjuvant therapies for resected stage III and IV melanoma has also been reported (23, 24).”
New pathways in immune stimulation: targeting OX40
Silva, C. A. C., Facchinetti, F., Routy, B., & Derosa, L. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000573 · Cited by 97
CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
Goltz, D., Gevensleben, H., Vogt, T. J., Dietrich, J., Golletz, C., Bootz, F., Kristiansen, G., Landsberg, J., & Dietrich, D. (2018) · JCI Insight · doi:10.1172/jci.insight.96793 · Cited by 96
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 102
Quek, C. Y. J., Pratapa, A., Bai, X., Al‐Eryani, G., da Silva, I. P., Mayer, A. T., Bartoniček, N., Harvey, K., Maher, N. G., Conway, J. W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114392 · Cited by 107
Self-citationKim, J., Kim, B., Kang, S. Y., Heo, Y. J., Park, S. H., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00314 · Cited by 98
“(2) We used RECIST criteria instead of iRECIST criteria.”
MethodAl-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16324 · Cited by 87
Ando, Y., Hayashi, T., Sugimoto, R., Nishibe, S., Ito, K., Kawada, K., Ikeda, Y., Yamada, S., & Imaizumi, K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00881-6 · Cited by 89
Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019
Kahlon, N., Doddi, S., Yousif, R., Najib, S., Sheikh, T., Abuhelwa, Z., Burmeister, C., & Hamouda, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45269 · Cited by 100
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
Santoni, M., Massari, F., Nunno, V. D., Conti, A., Cimadamore, A., Scarpelli, M., Montironi, R., Liang Cheng, C., Battelli, N., & Antonio Lopez-beltran, B. (2018) · Drugs in Context · doi:10.7573/dic.212528 · Cited by 86
Eggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.020 · Cited by 91
Self-citationShen, S., Hadley, M. M., Ustinova, K., Pavlíček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 86
Li, T., Zhang, C., Zhao, G., Zhang, X., Hao, M., Hassan, S., Zhang, M., Zheng, H., Yang, D., Liu, L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.036 · Cited by 93
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Liang, Y., Liu, X., Shen, L., Hu, G., Zou, G., Zhang, N., Chen, C., Chen, X., Zhu, X., Yuan, Y., et al. (2025) · JAMA · doi:10.1001/jama.2025.1132 · Cited by 87
Self-citationUltrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Dinnes, J., di Ruffano, L. F., Takwoingi, Y., Cheung, S. T., Nathan, P., Matin, R., Chuchu, N., Chan, S. A., Durack, A., Bayliss, S. E., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012806.pub2 · Cited by 106
Tandon, P., Bourassa‐Blanchette, S., Bishay, K., Parlow, S., Laurie, S. A., & McCurdy, J. D. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000213 · Cited by 88
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo, A., Chan, Y., Beaulieu, C., Kong, S., Cheung, W. Y., Monzon, J. G., Smylie, M., Walker, J., Morris, D., & Cheng, T. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0674 · Cited by 83
“Moreover, the efficacy of adjuvant anti-PD-1–directed immunotherapy in which the TME is essentially absent provides clinical evidence supporting the systemic immunity hypothesis [28].”
BackgroundSelf-citationVetto, J. T., Hsueh, E. C., Gastman, B., Dillon, L. D., Monzon, F. A., Cook, R. W., Keller, J. K., Huang, X., Fleming, A. M., Hewgley, P. W., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0912 · Cited by 86
Tsuruta, A., Shiiba, Y., Matsunaga, N., Fujimoto, M., Yoshida, Y., Koyanagi, S., & Ohdo, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0786 · Cited by 93
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
The new era of adjuvant therapies for melanoma
Eggermont, A. M. M., Robert, C., & Ribas, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0048-5 · Cited by 82
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 86
“%) patients treated with nivolumab developed thyroid irAEs (16,18–25).”
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Zaremba, A., Eggermont, A. M. M., Robert, C., Dummer, R., Ugurel, S., Livingstone, E., Ascierto, P. A., Long, G. V., Schadendorf, D., & Zimmer, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.002 · Cited by 92
Self-citationUnlocking the therapeutic potential of primary tumor-draining lymph nodes
Rotman, J., Koster, B. D., Jordanova, E. S., Heeren, A. M., & de Gruijl, T. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02330-y · Cited by 88
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long, J., Zhang, Q., & Rongxin, Z. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0086 · Cited by 91
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 81
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 86
“6% with adjuvant ipilimumab in patients with resected stage IIB-IV melanoma (12).”
BackgroundJansen, Y. J. L., Krüse, V., Corthals, J., Schats, K., van Dam, P., Seremet, T., Heirman, C., Brochez, L., Kockx, M. M., Thielemans, K., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02618-4 · Cited by 80
Holderried, T. A. W., de Vos, L., Bawden, E., Vogt, T. J., Dietrich, J., Zarbl, R., Bootz, F., Kristiansen, G., Brossart, P., Landsberg, J., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0752-8 · Cited by 82
Lanier, C. M., Hughes, R. T., Ahmed, T., LeCompte, M. C., Masters, A. H., Petty, W. J., Ruiz, J., Triozzi, P. L., Su, J., O’Neill, S., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz004 · Cited by 79
Luke, J. J., Ascierto, P. A., Carlino, M. S., Gershenwald, J. E., Grob, J., Hauschild, A., Kirkwood, J. M., Long, G. V., Mohr, P., Robert, C., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0666 · Cited by 78
Self-citationChorti, E., Kanaki, T., Zimmer, L., Hadaschik, E. N., Ugurel, S., Gratsias, E., Roesch, A., Bonella, F., Wessendorf, T., Wälscher, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.024 · Cited by 84
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 81
“CheckMate 238 trial, or adjuvant pembrolizumab based on the results of the recent phase III clinical trial (46% of panelists) [31, 32, 37].”
BackgroundSelf-citationCeci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · Cancers · doi:10.3390/cancers12113401 · Cited by 85
“The same anti-PD-1 agents are also prescribed in an adjuvant setting for completely resected melanoma with lymph node involvement or metastatic disease [81] and are currently under investigation as neoadjuvant treatment [82–84] for resectable stage III melanoma.”
BackgroundTargeted Therapy and Immunotherapy in Melanoma
Lazaroff, J. M., & Bolotin, D. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.007 · Cited by 83
Corticosteroid-resistant immune-related adverse events: a systematic review
Daetwyler, E., Wallrabenstein, T., König, D., Cappelli, L. C., Naidoo, J., Zippelius, A., & Laubli, H. P. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007409 · Cited by 89
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 80
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 76
“Immune checkpoint inhibitors (ICIs) used as a single agent or in combination with other types of ICIs or chemotherapy has markedly improved patient outcomes in advanced and metastatic settings (3-7).”
BackgroundVulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment
Wohlmuth, C., & Wieser, I. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00614-7 · Cited by 85
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 80
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R., & Gunton, J. E. (2023) · Diabetes Care · doi:10.2337/dc22-2202 · Cited by 68
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
da Silva, I. P., Wang, K. Y. X., Wilmott, J. S., Holst, J., Carlino, M. S., Park, J., Quek, C. Y. J., Wongchenko, M. J., Yan, Y., Mann, G. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1680 · Cited by 76
“In addition to exploring clinical trial data in the metastatic setting, data from the adjuvant clinical trials should also be explored by BRAF mutation genotype (4, 48, 49).”
BackgroundMethodSelf-citationPavlick, A., Blazquez, A. B., Meseck, M., Lattanzi, M., Ott, P. A., Marron, T. U., Holman, R. M., Mandeli, J., Salazar, A. M., McClain, C. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0545 · Cited by 75
“Given the favorable toxicity profile and immunogenicity of NY-ESO-1 vaccines, future trials should consider testing NY-ESO-1 antigen with poly-ICLC and montanide in combination with checkpoint blockade immunotherapy in the patient with high-risk resected melanoma, as this is now standard of care in this setting (2, 4,…”
BackgroundRisk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
Gergely, T. G., Kucsera, D., Tóth, V. É., Kovács, T., Sayour, N. V., Drobni, Z. D., Ruppert, M., Petrovich, B., Ágg, B., Onódi, Z., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15984 · Cited by 82
“Therefore, tumour-free patients treated with adjuvant ICI therapy to prevent recurrence (Weber et al., 2017) may still be at risk for ICI-induced cardiotoxicity.”
BackgroundKeller, J. K., Schwartz, T. L., Lizalek, J., Chang, E., Patel, A. D., Hurley, M. Y., & Hsueh, E. C. (2019) · Cancer Medicine · doi:10.1002/cam4.2128 · Cited by 75
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 86
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Taylor, C. A., Watson, R. A., Tong, O., Ye, W., Nassiri, I., Gilchrist, J. J., Aires, A. V. D. L., Sharma, P. K., Koturan, S., Cooper, R. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02095-5 · Cited by 86
Self-citationEgger, M. E., Scoggins, C. R., & McMasters, K. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07828-4 · Cited by 73
Melanoma brain metastases – Interdisciplinary management recommendations 2020
Gutzmer, R., Vordermark, D., Hassel, J. C., Krex, D., Wendl, C. M., Schadendorf, D., Sickmann, T., Rieken, S., Pukrop, T., Höeller, C., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102083 · Cited by 76
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 76
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 81
“74 In this study, 906 patients with stage IIIB, IIIC, and resected stage IV melanoma were randomized 1:1 to receive either nivolumab 3 mg/kg every 2 weeks for up to 1 year or ipilimumab 10 mg/kg every 3 weeks for four doses, followed by every 12 weeks for up to 1 year.”
MethodGarbe, C., Keim, U., Suciu, S., Amaral, T. M. S., Eigentler, T., Gesierich, A., Hauschild, A., Heinzerling, L., Kiecker, F., Schadendorf, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03034 · Cited by 82
“49).(4,18,27) Nivolumab was subsequently approved in both the United States and Europe for the adjuvant treatment of stage III melanoma.”
BackgroundUsyk, M., Pandey, A., Hayes, R. B., Moran, U., Pavlick, A. C., Osman, I., Weber, J. S., & Ahn, J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00974-z · Cited by 81
Self-citationComplementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Paulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 75
Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.004 · Cited by 75
Self-citationNeoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S., Fanchi, L., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 70
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies
Noble, C. W., Gangaputra, S. S., Thompson, I., Yuan, A., Apolo, A. B., Lee, J., Papaliodis, G. N., Kodati, S., Bishop, R. J., Magone, M. T., et al. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1583347 · Cited by 70
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Lucci, A., Hall, C. S., Patel, S. P., Narendran, B., Bauldry, J. B. B., Royal, R. E., Karhade, M., Upshaw, J. R., Wargo, J. A., Glitza, I. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2670 · Cited by 70
“2–3 LN or in transit without nodes 65 27 23/90 (26) 42/153 (27) >3 LN, matted or in transit with nodes 83 34 30/90 (33) 53/153 (35)”
Head and neck mucosal melanoma: The United Kingdom national guidelines
Nenclares, P., Dafydd, D. A., Bagwan, I., Begg, D., Kerawala, C. J., King, E. V., Lingley, K., Paleri, V., Paterson, G., Payne, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.017 · Cited by 68
“New studies support a potential role for systemic adjuvant therapy with immune checkpoint inhibitors or targeted therapies after complete resection of high-risk (stages III and IV) melanoma, regardless of primary location [25,26].”
BackgroundDousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 83
“PD-1 inhibitors (pembrolizumab and nivolumab) have been approved by the US Food and Drug Administration for metastatic melanoma, and recently in the adjuvant setting in stage III melanoma.(3,4) Although response rates (RR) are durable and remarkable, only approximately 35%-45% of patients benefit from these costly dru…”
BackgroundSelf-citationVerver, D., Klaveren, D. V., van Akkooi, A. C. J., Rutkowski, P. L., Powell, B. W. E. M., Robert, C., Testori, A., van Leeuwen, B. L., van der Veldt, A. A. M., Keilholz, U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.022 · Cited by 67
Self-citationStein, C., Burtey, S., Mancini, J., Pelletier, M., Sallée, M., Brunet, P., Berbis, P., Grob, J., Honoré, S., Gaudy‐Marqueste, C., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa137 · Cited by 69
Self-citation
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.